Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

48.75 -2.80 (-5.43%)
Delayed Quote Updated: 1:45 PM EST, Nov 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
What Scholar Rock (SRRK) Said on Its Q3 Earnings Call ↗
Scholar Rock (NASDAQ:SRRK) reported $0.6 million in third-quarter revenue from initial shipments of its newly approved spinal muscular atrophy treatment ISEMBYLD, while executives said insurance and... 
Via MarketBeat
Topics Earnings
Scholar Rock (NASDAQ:SRRK) Q3 2026 Results: ISEMBYLD Launch, Revenue Beat, and Stock Pullback ↗
Via Chartmill
News headline image
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab ↗
Scholar Rock (NASDAQ:SRRK) CEO David Hallal said the company is preparing for a September 30 FDA decision date for apitegromab, its investigational treatment for spinal muscular atrophy, or SMA,... 
Via MarketBeat
News headline image
Scholar Rock (SRRK) Q2 2026 Earnings Call Transcript ↗
Apitegromab awaits FDA decision on Sept. 30 for spinal muscular atrophy treatment. 
Via The Motley Fool
Topics Earnings Economy
Scholar Rock (NASDAQ:SRRK) Rallies 17% as Regulatory Catalysts Outweigh In-Line Q2 Results ↗
Via Chartmill
Scholar Rock (SRRK) Q1 Loss Narrows In Line Awaits PDUFA Decision ↗
Via Chartmill
Scholar Rock Holding Corp (NASDAQ:SRRK) Posts Q4 Loss, Awaits Apitegromab Approval in 2026 ↗
Via Chartmill
News headline image
Scholar Rock Q2 Earnings Call Highlights ↗
Scholar Rock (NASDAQ:SRRK) said its resubmitted biologics license application for apitegromab remains on track for a U.S. Food and Drug Administration decision by its Sept. 30 PDUFA date, as the... 
Via MarketBeat
Topics Earnings
News headline image
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗
Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗
This clinical-stage biotech develops targeted therapies for RAS/MAPK pathway-driven cancers, addressing hard-to-treat tumor types. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Scholar Rock Q1 Earnings Call Highlights ↗
Scholar Rock (NASDAQ:SRRK) said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company’s investigational treatment for... 
Via MarketBeat
Topics Earnings
News headline image
Scholar Rock (SRRK) Q1 2026 Earnings Transcript ↗
Scholar Rock (SRRK) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Scholar Rock (SRRK) Q4 2025 Earnings Transcript ↗
Scholar Rock (SRRK) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗
Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies. 
Via The Motley Fool
News headline image
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗
This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗
This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗
Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗
Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026 ↗
The Chief Scientific Officer of Scholar Rock Holding Corp has made multiple filings regarding disposals in January 2026, but this should not alarm investors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Nasdaq Bears Dig In: Short Interest Hits Record 18.38 Billion Shares Amid Valuation Anxiety
As the final trading days of 2025 approach, the Nasdaq has reached a staggering milestone that has both bulls and bears on edge. According to the latest settlement data released on December 15, 2025,... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗
This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Why Is Scholar Rock Holding Stock Climbing Today? ↗
Scholar Rock shares jump after the company strengthened its cash runway into 2027 and advanced launch preparations for its lead drug candidate, apitegromab. 
Via Benzinga
News headline image
Why Did Scholar Rock Soar 26% Today? ↗
The company is planning to reapply for approval of a muscle atrophy therapy in the coming year. 
Via Stocktwits
Topics Earnings
News headline image
Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday. 
Via Chartmill
News headline image
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Scholar Rock Holding Corp (NASDAQ:SRRK) Posts Wider-Than-Expected Q3 2025 Loss Amid Key Launch Preparations ↗
Scholar Rock invests heavily in its lead drug apitegromab, targeting a 2026 launch for spinal muscular atrophy despite a wider Q3 2025 loss. 
Via Chartmill
News headline image
Earnings Scheduled For November 14, 2025 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.